X4 Pharmaceuticals (NASDAQ: XFOR) revenue
X4 Pharmaceuticals reported revenue of $35.1m for fiscal 2025, 1,250.5% more than in fiscal 2024 ($2.6m).
Fiscal 2025 is the highest of the 8 fiscal years on record for X4 Pharmaceuticals.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $35.1m | +1,250.5% | −$86.9m | −247.4% |
| 2024 | $2.6m | — | −$36.4m | −1,400.0% |
| 2023 | $0.0m | — | −$107.5m | — |
| 2022 | $0.0m | — | −$87.6m | — |
| 2021 | $0.0m | −100.0% | −$85.1m | — |
| 2020 | $3.0m | — | −$59.9m | −1,995.8% |
| 2019 | $0.0m | — | −$51.7m | — |
| 2018 | $0.0m | — | −$29.1m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
X4 Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, X4 Pharmaceuticals ranks 345th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; X4 Pharmaceuticals, 1,250.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 343rd | C4 Therapeutics | $35.9m | 1.0% |
| 344th | Senseonics | $35.3m | 56.9% |
| 345th | X4 Pharmaceuticals | $35.1m | 1,250.5% |
| 346th | Precision Biosciences | $34.3m | −50.1% |
| 347th | Orchestra BioMed | $33.5m | 1,169.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of X4 Pharmaceuticals
- How much revenue did X4 Pharmaceuticals make in fiscal 2025?
- X4 Pharmaceuticals reported revenue of $35.1m for fiscal 2025, compared with $2.6m in fiscal 2024.
- What was the best year for revenue at X4 Pharmaceuticals?
- Of its last 8 fiscal years, fiscal 2025, with $35.1m.
- Where does X4 Pharmaceuticals rank in its sector by revenue?
- It ranks 345th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for X4 Pharmaceuticals come from?
- From the annual report (Form 10-K) that X4 Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that X4 Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on X4 Pharmaceuticals: the X4 Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.